Jeffrey N. Myers

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Supplementary Table S5A. Bulk-level single cell ATAC sequencing analysis showing immediate (short-term) chromatin openings (peaks) in HN30-P cells following CDDP treatment; Supplementary Table S5B. Bulk-level single cell ATAC sequencing analysis showing long-term chromatin openings (peaks) gained in cisplatin-resistant HN30-R8 cells following CDDP treatment.

Year:

2025

Purpose: Alterations in the KEAP1 / NFE2L2 (NRF2)/ CUL3 pathway occur in ∼20% of human head and neck squamous cell carcinomas (HNSCC) and are associated with resistance to standard-of-care therapy. However, this pathway’s role in radiotherapy resistance in HNSCC has not been well studied. Experimental Design: We generated genetically engineered mouse models and developed primary murine cancer cell lines harboring mutations commonly observed in human HNSCC, including inducible activation of PIK3CA and deletion of Trp53 , with or without Keap1 loss. Primary tumors were initiated via 4-hydroxytamoxifen injection ± the tobacco carcinogen benzo[a]pyrene (BAP) into the oral buccal mucosa. Tumors were analyzed by Western blotting, IHC, and RNA sequencing and subjected to fractionated radiotherapy to investigate the role of the KEAP1/NRF2 pathway in radioresistance and modulation of the tumor-immune microenvironment. Results: BAP exposure accelerated primary tumor formation within 1 month, with histologic analysis confirming invasive squamous cell carcinoma, validated by cytokeratin and differentiation marker expression. Primary cell lines derived from Keap1 -haploinsufficient tumors exhibited upregulation of NRF2 target genes and a radioresistant phenotype, which was reversed after Nrf2 knockdown in vitro . Bulk RNA sequencing revealed that Keap1 haploinsufficiency correlated with NRF2 pathway activation, increased myeloid infiltration, and enhanced angiogenic signatures. In vivo , Keap1 haploinsufficiency promoted accelerated tumor growth and decreased survival. Finally, using fractionated radiotherapy, we showed that Keap1 -haploinsufficient primary tumors were significantly more radioresistant than Keap1 -proficient tumors, regardless of BAP exposure. Conclusions: These data demonstrate that Keap1 haploinsufficiency in HNSCC is linked to unfavorable tumor-immune microenvironment, aggressive growth, and a radioresistant phenotype.

Year:

2025

Purpose: Neoadjuvant chemotherapy prior to definitive surgery has been used widely for locally advanced oral squamous cell carcinoma (OSCC). We evaluated neoadjuvant erlotinib with platinum-docetaxel versus placebo with platinum-docetaxel in patients with stage IIIIVB OSCC. Patients and Methods: Patients with newly diagnosed stage III, IVA, and IVB (American Joint Committee on Cancer 7th) OSCC amenable to surgical resection were included. Patients were randomized to receive up to 3 cycles of chemotherapy with concurrent erlotinib or placebo, followed by surgery. The primary endpoint was major pathologic response (MPR) rate; secondary endpoints included safety, overall survival (OS), and progression-free survival (PFS). Results: Fifty-two patients received at least 1 cycle of treatment and 47 were evaluable with surgical resection. MPR rate was not different between erlotinib (30%, 7/23) and placebo arms (41.7%, 10/24; P = 0.55). At median follow up of 26.5 months, there was no difference on OS or PFS between groups. Patients who received erlotinib with chemotherapy and achieved MPR ( n = 7) had no recurrence. The treatment-related adverse event rates were not different between the two groups (96% vs. 96%). However, rash, mostly low grade, was more common in the erlotinib arm (79% vs. 50%). Transcriptomic analysis in the pretreatment samples indicated that genes in protein glycosylation and Wnt signaling pathways were associated with benefit in those treated with erlotinib plus chemotherapy. Conclusions: The addition of erlotinib to platinum-taxane chemotherapy was well tolerated but did not induce higher rates of MPR or PFS or OS survival benefit. Patients who received chemotherapy with erlotinib and achieved major pathologic responses had excellent clinical outcome.

Year:

2025

Purpose: Radiation and platinum-based chemotherapy form the backbone of therapy in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). We have correlated focal adhesion kinase (FAK/ PTK2 ) expression with radioresistance and worse outcomes in these patients. However, the importance of FAK in driving radioresistance and its effects on chemoresistance in these patients remains unclear. Experimental Design: We performed an in vivo shRNA screen using targetable libraries to identify novel therapeutic sensitizers for radiation and chemotherapy. Results: We identified FAK as an excellent target for both radio- and chemosensitization. Because TP53 is mutated in over 80% of HPV-negative HNSCC, we hypothesized that mutant TP53 may facilitate FAK-mediated therapy resistance. FAK inhibitor increased sensitivity to radiation, increased DNA damage, and repressed homologous recombination and nonhomologous end joining repair in mutant, but not wild-type, TP53 HPV-negative HNSCC cell lines. The mutant TP53 cisplatin-resistant cell line had increased FAK phosphorylation compared with wild-type, and FAK inhibition partially reversed cisplatin resistance. To validate these findings, we utilized an HNSCC cohort to show that FAK copy number and gene expression were associated with worse disease-free survival in mutant TP53 , but not wild-type TP53 , HPV-negative HNSCC tumors. Conclusions: FAK may represent a targetable therapeutic sensitizer linked to a known genomic marker of resistance.

Year:

2024

Purpose: Radiation and platinum-based chemotherapy form the backbone of therapy in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). We have correlated focal adhesion kinase (FAK/ PTK2 ) expression with radioresistance and worse outcomes in these patients. However, the importance of FAK in driving radioresistance and its effects on chemoresistance in these patients remains unclear. Experimental Design: We performed an in vivo shRNA screen using targetable libraries to identify novel therapeutic sensitizers for radiation and chemotherapy. Results: We identified FAK as an excellent target for both radio- and chemosensitization. Because TP53 is mutated in over 80% of HPV-negative HNSCC, we hypothesized that mutant TP53 may facilitate FAK-mediated therapy resistance. FAK inhibitor increased sensitivity to radiation, increased DNA damage, and repressed homologous recombination and nonhomologous end joining repair in mutant, but not wild-type, TP53 HPV-negative HNSCC cell lines. The mutant TP53 cisplatin-resistant cell line had increased FAK phosphorylation compared with wild-type, and FAK inhibition partially reversed cisplatin resistance. To validate these findings, we utilized an HNSCC cohort to show that FAK copy number and gene expression were associated with worse disease-free survival in mutant TP53 , but not wild-type TP53 , HPV-negative HNSCC tumors. Conclusions: FAK may represent a targetable therapeutic sensitizer linked to a known genomic marker of resistance.

Year:

2024

Purpose: Cisplatin (CDDP)-based chemotherapy is a first-line treatment for patients with advanced head and neck squamous cell carcinomas (HNSCC), despite a high rate of treatment failures, acquired resistance, and subsequent aggressive behavior. The purpose of this study was to study the mechanism of CDDP resistance and metastasis in HNSCC. We investigated the role of NRF2 pathway activation as a driven event for tumor progression and metastasis of HNSCC. Experimental Design: Human HNSCC cell lines that are highly resistant to CDDP were generated. Clonogenic survival assays and a mouse model of oral cancer were used to examine the impact of NRF2 activation in vitro and in vivo on CDDP sensitivity and development of metastasis. Western blotting, immunostaining, whole-exome sequencing, single-cell transcriptomic and epigenomic profiling platforms were performed to dissect clonal evolution and molecular mechanisms. Results: Implantation of CDDP-resistant HNSCC cells into the tongues of nude mice resulted in a very high rate of distant metastases. The CDDP-resistant cells had significantly higher expression of NRF2 pathway genes in the presence of newly acquired KEAP1 mutations, or via epigenomic activation of target genes. Knockdown of NRF2 or restoration of the wild-type KEAP1 genes resensitized resistant cells to CDDP and decreased distant metastasis (DM). Finally, treatment with inhibitor of glutaminase-1, a NRF2 target gene, alleviated CDDP resistance. Conclusions: CDDP resistance and development of DM are associated with dysregulated and epigenetically reprogrammed KEAP1–NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP-resistant head and neck tumors.

Year:

2023

Collaborators (25)

Xiuning Le

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Heath Skinner

Professor & Chair

University of Pittsburgh

UNITED STATES
View details

Gordon Mills

Professor

Oregon Health & Science University

UNITED STATES
View details

Jeffrey Everitt

Duke University

UNITED STATES
View details

Kunal Rai

Associate Professor

The University of Texas MD Anderson Cancer Center Children's Cancer Hospital

UNITED STATES
View details

Curtis R. Pickering

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anand Singh

Senior Research Scientist

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Phillip Pifer

Assistant Professor

West Virginia University Hospitals

UNITED STATES
View details

W. Fraser Symmans

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Vlad Sandulache

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

John V. Heymach

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Katarzyna Tomczak

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jiexin Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rutulkumar Patel

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Beth M. Beadle

Professor

Stanford University

UNITED STATES
View details

FREDERICO OMAR GLEBER NETTO

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

LI SHEN

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Maura L. Gillison

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Patricia Castro

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Yvonne Mowery

Associate Professor

UPMC Hillman Cancer Center

UNITED STATES
View details

Faye M. Johnson

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Abdullah Osman

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details